Wall Street analysts expect Burlington Stores (BURL) to post quarterly earnings of $1.59 per share in its upcoming report, which indicates a year-over-year increase of 2.6%. Revenues are expected to be $2.71 billion, up 7.1% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, ...

The upcoming report from HP (HPQ) is expected to reveal quarterly earnings of $0.92 per share, indicating a decline of 1.1% compared to the year-ago period. Analysts forecast revenues of $15.02 billion, representing an increase of 6.9% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prio ...

The upcoming report from Gap (GAP) is expected to reveal quarterly earnings of $0.58 per share, indicating a decline of 19.4% compared to the year-ago period. Analysts forecast revenues of $3.91 billion, representing an increase of 2.2% year over year.Over the last 30 days, there has been an upward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this ti ...

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.31 per share, a 4% increase year-over-year, with revenues projected at $8.86 billion, reflecting a 5.4% increase from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts project 'Net Sales- World Wide Revenue- Diabetes' at $749.45 million, a 9.3% increase year-over-year [5] - 'Net Sales- World Wide Revenue- Neuroscience' is expected to reach $2.49 billion, reflecting a 1.5% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Cardiovascular' is forecasted at $3.36 billion, indicating an 8.5% increase year-over-year [6] - 'Net Sales- World Wide Revenue- Medical Surgical' is anticipated to be $2.24 billion, a 5.4% increase from the previous year [6] - 'Net Sales- U.S. Revenue' is projected at $4.53 billion, reflecting a 5.3% increase year-over-year [6] Specific Segment Estimates - 'Net Sales- U.S. Revenue- Medical Surgical' is expected to be $938.99 million, showing a slight decline of 0.5% year-over-year [7] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $351.65 million, a 5.6% increase from the prior year [7] - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is estimated at $326.68 million, indicating a 6.1% increase year-over-year [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is expected to be $319.41 million, reflecting a minimal change of +0.1% year-over-year [8] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $1.03 billion, indicating a 5.4% increase year-over-year [9] - 'Net Sales- ROW- Cardiovascular' is expected to reach $1.80 billion, reflecting a 7.8% increase from the prior year [9] Stock Performance - Over the past month, Medtronic shares have returned +0.5%, compared to the Zacks S&P 500 composite's +4.6% change, suggesting that MDT is likely to perform in line with the overall market [9]

Core Insights - Chevron reported a revenue of $49.73 billion for the quarter ended September 2025, reflecting a decrease of 1.9% year-over-year and falling short of the Zacks Consensus Estimate of $53.58 billion by 7.19% [1] - The company's EPS was $1.85, down from $2.51 in the same quarter last year, but exceeded the consensus estimate of $1.66 by 11.45% [1] Financial Performance Metrics - Total net oil-equivalent production reached 4,086 million barrels, surpassing the average analyst estimate of 3,927.88 million barrels [4] - U.S. upstream net oil-equivalent production per day was 2,040 million barrels, exceeding the analyst estimate of 1,950.41 million barrels [4] - International upstream net oil-equivalent production per day was 2,046 million barrels, above the average estimate of 1,977.47 million barrels [4] - U.S. upstream revenue from natural gas realization was $1.77 per thousand cubic feet, higher than the estimated $1.65 [4] - U.S. upstream net natural gas production per day was 3,265 Mcf/D, exceeding the estimate of 3,094.04 Mcf/D [4] - Worldwide net natural gas production per day was 8,939 Mcf/D, above the estimate of 8,593.22 Mcf/D [4] - Worldwide net crude oil and natural gas liquids production per day was 2,595 million barrels, surpassing the estimate of 2,508.3 million barrels [4] - U.S. upstream net crude oil and natural gas liquids production per day was 1,496 million barrels, exceeding the estimate of 1,437.54 million barrels [4] - International upstream net natural gas production per day was 5,674 Mcf/D, above the estimate of 5,499.18 Mcf/D [4] Revenue Breakdown - Other income was reported at $576 million, significantly higher than the estimated $263.75 million, representing a year-over-year increase of 19.5% [4] - Income from equity affiliates was $981 million, compared to the average estimate of $388.79 million, showing a year-over-year decline of 22.2% [4] - Sales and other operating revenues were $48.17 billion, below the average estimate of $50.13 billion, reflecting a year-over-year decrease of 1.6% [4] Stock Performance - Chevron's shares returned +0.9% over the past month, while the Zacks S&P 500 composite experienced a -0.2% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - American Healthcare REIT (AHR) reported revenue of $572.94 million for Q3 2025, a 9.4% increase year-over-year, with an EPS of $0.44 compared to -$0.03 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $565.26 million by 1.36%, and the EPS also surpassed the consensus estimate of $0.42 by 4.76% [1] Revenue Breakdown - Resident fees and services generated $532.06 million, slightly below the two-analyst average estimate of $535.68 million, reflecting an 11.6% year-over-year increase [4] - Real estate revenue was reported at $40.88 million, exceeding the average estimate of $39.47 million, but showing a 13% decline year-over-year [4] Stock Performance - Over the past month, shares of American Healthcare REIT have returned +17.2%, significantly outperforming the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Blue Owl Capital Corporation reported $453.07 million in revenue for Q3 2025, marking an 11.6% year-over-year increase, but fell short of the Zacks Consensus Estimate by 1.84% [1] - The company's EPS for the same quarter was $0.36, down from $0.47 a year ago, representing a surprise of -7.69% compared to the consensus estimate of $0.39 [1] Financial Performance Metrics - Investment income from non-controlled, non-affiliated investments showed a total of $403.35 million, a 9.7% increase year-over-year, but below the average estimate of $412.83 million [4] - Interest income from non-controlled, non-affiliated investments was reported at $349.05 million, reflecting a 16.5% year-over-year increase, yet it was lower than the average estimate of $356.5 million [4] - Total investment income from controlled, affiliated investments reached $48.4 million, exceeding the average estimate of $42.95 million, with a year-over-year change of 28.2% [4] - Dividend income from controlled, affiliated investments was reported at $37.92 million, surpassing the average estimate of $33.13 million, with a year-over-year increase of 28% [4] - The stock of Blue Owl Capital Corporation has returned +3% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3]

Core Insights - Hub Group reported revenue of $934.5 million for the quarter ended September 2025, reflecting a year-over-year decline of 5.3% and an EPS of $0.49 compared to $0.52 a year ago, with a slight revenue surprise of +0.58% over the Zacks Consensus Estimate of $929.12 million [1] Financial Performance - Operating Revenue from Intermodal and Transportation Solutions was $561.49 million, exceeding the three-analyst average estimate of $539.45 million, with a year-over-year change of +0.3% [4] - Operating Revenue from Inter-segment eliminations was reported at $-29.39 million, slightly worse than the estimated $-28.14 million, showing a year-over-year decline of -13.4% [4] - Operating Revenue from Logistics was $402.4 million, below the average estimate of $418.62 million, representing a year-over-year decrease of -12.7% [4] Market Performance - Hub Group's shares have returned +6.5% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change, although the stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near term [3]

Core Insights - Axos Financial reported revenue of $323.39 million for the quarter ended September 2025, reflecting a year-over-year increase of 0.9% and a surprise of +0.79% over the Zacks Consensus Estimate of $320.85 million [1] - The company's EPS for the quarter was $2.07, up from $1.96 in the same quarter last year, resulting in an EPS surprise of +11.29% compared to the consensus estimate of $1.86 [1] Financial Metrics - The efficiency ratio was reported at 48.3%, slightly above the average estimate of 47.2% based on two analysts [4] - The net interest margin stood at 4.8%, matching the average estimate from two analysts [4] - Net annualized charge-offs to average loans were 0.1%, consistent with the average estimate of 0.1% from two analysts [4] - Total non-interest income was $32.34 million, exceeding the average estimate of $32.09 million based on two analysts [4] - Net interest income was reported at $291.05 million, surpassing the average estimate of $288.73 million from two analysts [4] Stock Performance - Over the past month, shares of Axos Financial have returned -5.7%, contrasting with the Zacks S&P 500 composite's increase of +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Beacon Financial reported revenue of $144.95 million for the quarter ended September 2025, reflecting a year-over-year increase of 32.3% [1] - The company's EPS was $0.44, down from $0.58 in the same quarter last year, indicating a significant decline [1] - Revenue exceeded the Zacks Consensus Estimate of $144.1 million by 0.59%, while the EPS fell short of the consensus estimate of $0.85 by 48.24% [1] Financial Performance Metrics - Total earning assets averaged $14.23 billion, surpassing the estimated $12.87 billion [4] - The net interest margin was reported at 3.7%, exceeding the average estimate of 3.2% [4] - Total non-interest income was $12.35 million, significantly below the average estimate of $20.63 million [4] - Net interest income reached $132.61 million, compared to the estimated $90.84 million [4] Stock Performance - Over the past month, Beacon's shares returned +0.8%, while the Zacks S&P 500 composite increased by +3.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]